FGF-16 Activators are chemical compounds that specifically influence signaling events leading to the direct or indirect activation of FGF-16. These compounds work by targeting various cellular pathways that FGF-16 is involved in. For instance, LY294002 inhibits PI3K, leading to an enhanced activation of FGF-16, which operates downstream of the PI3K pathway. Similarly, U0126 is a MEK1/2 inhibitor, and its inhibition can lead to FGF-16 activation through the ERK pathway, where FGF-16 is a known participant. SB203580, a p38 MAPK inhibitor, can also enhance FGF-16 activation, as FGF-16 is a part of the MAPK signaling pathway. Other compounds such as Rapamycin, an mTOR inhibitor, and Bay 11-7082, an NF-kB inhibitor, act on key regulators of cell growth and proliferation, processes that FGF-16 is involved in. By inhibiting these factors, these compounds can indirectly enhance FGF-16 activity. PD98059, a MEK inhibitor, and SP600125, a JNK inhibitor, can also increase FGF-16 activation through the MAPK/ERK pathway. Similarly, Akt Inhibitor IV inhibits the PI3K/Akt pathway, and Y-27632 inhibits ROCK, both of which can enhance the demand for FGF-16 activation. Lastly, BAPTA-AM, a calcium chelator, and Docosahexaenoic Acid (DHA), an omega-3 fatty acid, can activate FGF-16 through the modulation of cellular calcium levels and the PI3K/Akt pathway respectively.
In essence, these FGF-16 activators, by their influence on specific pathways or cellular processes, can lead to the increased functional activity of FGF-16. While they have distinct targets and operate through different mechanisms, their cumulative effect is to enhance FGF-16 activation, either directly or indirectly. For example, Bay 11-7082 inhibits NF-kB, a transcription factor that regulates genes controlling cell proliferation. By inhibiting NF-kB, it can indirectly enhance FGF-16 activity, which is known to be involved in cell proliferation. Similarly, Y-27632 inhibits ROCK, which is involved in actin cytoskeleton formation. By inhibiting ROCK, it can enhance the demand for FGF-16 activation, which is known to be involved in the process of cytoskeleton formation. Thus, these compounds complement the normal function of FGF-16 by influencing related pathways and cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of PI3K. By inhibiting PI3K, it can increase the demand for FGF-16 activation as FGF-16 operates downstream of this pathway. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin can activate adenylate cyclase, which increases intracellular cAMP levels. This, in turn, can activate the cAMP-dependent protein kinase (PKA) pathway, leading to enhanced FGF-16 activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. As FGF-16 is involved in the MAPK pathway, the inhibition of p38 MAPK can lead to increased FGF-16 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. mTOR is a key regulator of cell growth and proliferation, processes in which FGF-16 is involved. Inhibition of mTOR can lead to increased FGF-16 activity. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Bay 11-7082 inhibits NF-kB activation. As NF-kB is a transcription factor that regulates genes controlling cell proliferation, inhibiting it can indirectly enhance FGF-16 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of MEK, a part of the MAPK/ERK pathway. Inhibiting MEK can lead to an increase in FGF-16 activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is a selective inhibitor of JNK. As FGF-16 is involved in the MAPK pathway, inhibiting JNK can lead to an increase in FGF-16 activation. | ||||||
Akt Inhibitor IV | 681281-88-9 | sc-203809 sc-203809A | 5 mg 25 mg | $173.00 $695.00 | 42 | |
Akt Inhibitor IV is a PI3K/Akt pathway inhibitor. By inhibiting this pathway, it can enhance the demand for FGF-16 activation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is an inhibitor of ROCK. As ROCK is involved in actin cytoskeleton formation, inhibiting it can enhance the demand for FGF-16 activation. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
BAPTA-AM is a cell-permeable calcium chelator. By modulating calcium levels, it can enhance the demand for FGF-16 activation. |